Management of atrial fibrillation (AF) is a very challenging situation for physicians.
In the light of this issue, we read the article by Nicholson et al. about “hemodynamic
comparison of intravenous push diltiazem versus metoprolol for atrial fibrillation
rate control” [
[1]
]. Although this article gives us unique informations, we want to address some points
that need more attention.To read this article in full you will need to make a payment
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of Emergency MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Hemodynamic comparison of intravenous push diltiazem versus metoprolol for atrial fibrillation rate control.Am J Emerg Med. 2020; 38: 1879-1883
- The imminent epidemic of atrial fibrillation and its concomitant diseases–myocardial infarction and heart failure-a cause for concern.Int J Cardiol. 2019; 287: 162-173
- Physiology, cardiac output. StatPearls.StatPearls Publishing., Treasure Island (FL)2020 (Copyright © 2020, StatPearls Publishing LLC)
- 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.Eur Heart J. 2020; : 1-125
Article Info
Publication History
Published online: November 04, 2020
Accepted:
October 31,
2020
Received:
September 15,
2020
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2020 Elsevier Inc. All rights reserved.
